Comparison

AbbVie Inc. (ABBV) vs Sanofi (SNY)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ABBV

AbbVie Inc.

Drug Manufacturers—General

Revenue, FY25: $61.16B
Net income: $4.23B
Operating cash flow: $19.03B
Free cash flow: $17.82B
Net margin: 6.91%
Operating margin: 24.65%
Gross margin: 70.24%

SNY

Sanofi

Drug Manufacturers—General

Revenue, FY25: $43.63B
Net income: $7.81B
Operating cash flow: $10.75B
Free cash flow: $7.21B
Net margin: 17.91%
Operating margin: 14.54%
Gross margin: 77.17%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ABBV	SNY
Revenue growth, latest filed year	+8.57%	+6.20%
Piotroski F-score	8 of 9	7 of 9
P/E against its own history	54.65% above	-

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ABBV

Reimbursement
Goodwill impairment
Litigation
Product recalls
FDA approval
Supply chain

And 16 more.

SNY

No 10-K read yet.

Tracked managers holding both

Dodge & Cox Dodge & Cox 0.00% · 0.63%

Updated Sep 17, 2026 · the newer of the two companies' filings